SENORES Q2 : CONS NET PROFIT UP 21.5% AT 36.6 CR (YOY), UP 20.2% (QOQ). STRONG (On 1st Look)

Revenue up 24.9% at 192.33 Cr (YOY), up 6.7% (QOQ). Ebitda up 38% at 58 Cr (YOY); margins ~30.2% v ~27.3% (YOY). Regulated Markets Q2 revenue up 27.9% (YOY); ANDAs at 64 v 34. FY27 outlook: 30-40% revenue growth and 50-60% PAT growth.

Senores Pharmaceuticals Ltd

Open attachment

← Back to feed